Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1).
Journal
Menopause (New York, N.Y.)
ISSN: 1530-0374
Titre abrégé: Menopause
Pays: United States
ID NLM: 9433353
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
pubmed:
1
2
2023
medline:
25
2
2023
entrez:
31
1
2023
Statut:
ppublish
Résumé
Neurokinin (NK)-3 and NK-1 receptors have been implicated in the etiology of vasomotor symptoms (VMS) and sleep disturbances associated with menopause. This phase 2b, adaptive, dose-range finding study aimed to assess the efficacy and safety of multiple doses of elinzanetant (NT-814), a selective NK-1,3 receptor antagonist, in women experiencing VMS associated with menopause, and investigate the impact of elinzanetant on sleep and quality of life. Postmenopausal women aged 40 to 65 years who experienced seven or more moderate-to-severe VMS per day were randomized to receive elinzanetant 40, 80, 120, or 160 mg or placebo once daily using an adaptive design algorithm. Coprimary endpoints were reduction in mean frequency and severity of moderate-to-severe VMS at weeks 4 and 12. Secondary endpoints included patient-reported assessments of sleep and quality of life. Elinzanetant 120 mg and 160 mg achieved reductions in VMS frequency versus placebo from week 1 throughout 12 weeks of treatment. Least square mean reductions were statistically significant versus placebo at both primary endpoint time points for elinzanetant 120 mg (week 4: -3.93 [SE, 1.02], P < 0.001; week 12: -2.95 [1.15], P = 0.01) and at week 4 for elinzanetant 160 mg (-2.63 [1.03]; P = 0.01). Both doses also led to clinically meaningful improvements in measures of sleep and quality of life. All doses of elinzanetant were well tolerated. Elinzanetant is an effective and well-tolerated nonhormone treatment option for postmenopausal women with VMS and associated sleep disturbance. Elinzanetant also improves quality of life in women with VMS.
Identifiants
pubmed: 36720081
doi: 10.1097/GME.0000000000002138
pii: 00042192-202303000-00003
pmc: PMC9970022
doi:
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
239-246Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The North American Menopause Society.
Déclaration de conflit d'intérêts
Financial disclosure/conflicts of interest: C.C. and L.Z. are employees of Bayer CC AG. C.S. is an employee of Bayer AG. M.K., S.P., E.B., S.S., and M.T. are employees of NeRRe Therapeutics. J.B., as an employee of Cytel Inc, was a paid statistical consultant on this trial. R.A.A. has undertaken consultancy work for NeRRe Therapeutics and Sojournix Inc. J.A.S. has grant/research support from AbbVie, Inc, Bayer Healthcare LLC, Daré Bioscience, Ipsen, Mylan/Viatris Inc, Myovant Sciences, ObsEva SA, Sebela Pharmaceuticals Inc, and Viveve Medical; has been a consultant/advisory boards of Bayer HealthCare Pharmaceuticals Inc, Besins Healthcare, California Institute of Integral Studies, Camargo Pharmaceutical Services, LLC, Covance Inc, Daré Bioscience, DEKA M.E.L.A. S.r.l., Femasys Inc, KaNDy/NeRRe Therapeutics Ltd, Khyria, Madorra Pty Ltd, Mitsubishi Tanabe Pharma Development America, Inc, QUE Oncology Pty, Limited, Scynexis Inc, Sebela Pharmaceuticals, Inc, Sprout Pharmaceuticals, Inc, and Vella Bioscience Inc; has served on the Speaker's bureaus of Mayne Pharma, Inc, Myovant Sciences, Inc, Pfizer Inc, Pharmavite LLC, Scynexis Inc, and TherapeuticsMD; and is a stockholder (direct purchase) in Sermonix Pharmaceuticals. N.P. has undertaken consultancy and speaker's bureau work for a number of pharmaceutical companies including Bayer AG. H.J. has received grant funding from National Institutes of Health, Merck, Pfizer, and Hello Therapeutics; has undertaken consultancy work for Bayer, Jazz, and Eisai; and her spouse is an employee at Arsenal Biosciences and has equity at Merck.
Références
Nappi RE, Kroll R, Siddiqui E, et al. Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause 2021;28:875–882. doi: 10.1097/GME.0000000000001793
doi: 10.1097/GME.0000000000001793
Thurston RC. Vasomotor symptoms: natural history, physiology, and links with cardiovascular health. Climacteric 2018;21:96–100. doi: 10.1080/13697137.2018.1430131
doi: 10.1080/13697137.2018.1430131
Thurston RC, Chang Y, Buysse DJ, Hall MH, Matthews KA. Hot flashes and awakenings among midlife women. Sleep 2019;42:zsz131. doi: 10.1093/sleep/zsz131
doi: 10.1093/sleep/zsz131
Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women's Health across the Nation. Obstet Gynecol Clin North Am 2011;38:489–501. doi: 10.1016/j.ogc.2011.05.006
doi: 10.1016/j.ogc.2011.05.006
Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015;175:531–539. doi: 10.1001/jamainternmed.2014.8063
doi: 10.1001/jamainternmed.2014.8063
Freeman EW, Sammel MD, Lin H, Liu Z, Gracia CR. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol 2011;117:1095–1104. doi: 10.1097/AOG.0b013e318214f0de
doi: 10.1097/AOG.0b013e318214f0de
Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause 2014;21:924–932. doi: 10.1097/GME.0000000000000196
doi: 10.1097/GME.0000000000000196
Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health 2006;96:1226–1235. doi: 10.2105/AJPH.2005.066936
doi: 10.2105/AJPH.2005.066936
Williams RE, Kalilani L, DiBenedetti DB, et al. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric 2008;11:32–43. doi: 10.1080/13697130701744696
doi: 10.1080/13697130701744696
de Villiers TJ, Gass ML, Haines CJ, et al. Global consensus statement on menopausal hormone therapy. Climacteric 2013;16:203–204. doi: 10.3109/13697137.2013.771520
doi: 10.3109/13697137.2013.771520
Biglia N, Bounous VE, De Seta F, Lello S, Nappi RE, Paoletti AM. Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update. Ecancermedicalscience 2019;13:909. doi: 10.3332/ecancer.2019.909
doi: 10.3332/ecancer.2019.909
Constantine GD, Graham S, Clerinx C, et al. Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countries. Post Reprod Health 2016;22:112–122. doi: 10.1177/2053369116632439
doi: 10.1177/2053369116632439
Neves-E-Castro M, Birkhauser M, Samsioe G, et al. EMAS position statement: the ten point guide to the integral management of menopausal health. Maturitas 2015;81:88–92. doi: 10.1016/j.maturitas.2015.02.003
doi: 10.1016/j.maturitas.2015.02.003
Rance NE, Dacks PA, Mittelman-Smith MA, Romanovsky AA, Krajewski-Hall SJ. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol 2013;34:211–227. doi: 10.1016/j.yfrne.2013.07.003
doi: 10.1016/j.yfrne.2013.07.003
Lehman MN, Coolen LM, Goodman RL. Minireview: kisspeptin/neurokinin B/dynorphin (KNDy) cells of the arcuate nucleus: a central node in the control of gonadotropin-releasing hormone secretion. Endocrinology 2010;151:3479–3489. doi: 10.1210/en.2010-0022
doi: 10.1210/en.2010-0022
Rance NE, McMullen NT, Smialek JE, Price DL, Young WS 3rd. Postmenopausal hypertrophy of neurons expressing the estrogen receptor gene in the human hypothalamus. J Clin Endocrinol Metab 1990;71:79–85. doi: 10.1210/jcem-71-1-79
doi: 10.1210/jcem-71-1-79
Rance NE, Young WS 3rd. Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalami of postmenopausal women. Endocrinology 1991;128:2239–2247. doi: 10.1210/endo-128-5-2239
doi: 10.1210/endo-128-5-2239
Rometo AM, Krajewski SJ, Voytko ML, Rance NE. Hypertrophy and increased kisspeptin gene expression in the hypothalamic infundibular nucleus of postmenopausal women and ovariectomized monkeys. J Clin Endocrinol Metab 2007;92:2744–2750. doi: 10.1210/jc.2007-0553
doi: 10.1210/jc.2007-0553
Padilla SL, Johnson CW, Barker FD, Patterson MA, Palmiter RD. A neural circuit underlying the generation of hot flushes. Cell Rep 2018;24:271–277. doi: 10.1016/j.celrep.2018.06.037
doi: 10.1016/j.celrep.2018.06.037
Borsay BA, Skrapits K, Herczeg L, et al. Hypophysiotropic gonadotropin-releasing hormone projections are exposed to dense plexuses of kisspeptin, neurokinin B and substance p immunoreactive fibers in the human: a study on tissues from postmenopausal women. Neuroendocrinology 2014;100(2-3):141–152. doi: 10.1159/000368362
doi: 10.1159/000368362
Hrabovszky E, Borsay BA, Racz K, et al. Substance P immunoreactivity exhibits frequent colocalization with kisspeptin and neurokinin B in the human infundibular region. PLoS One 2013;8:e72369. doi: 10.1371/journal.pone.0072369
doi: 10.1371/journal.pone.0072369
Navarro VM, Bosch MA, Leon S, et al. The integrated hypothalamic tachykinin-kisspeptin system as a central coordinator for reproduction. Endocrinology 2015;156:627–637. doi: 10.1210/en.2014-1651
doi: 10.1210/en.2014-1651
Trower M, Anderson RA, Ballantyne E, Joffe H, Kerr M, Pawsey S. Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. Menopause 2020;27:498–505. doi: 10.1097/GME.0000000000001500
doi: 10.1097/GME.0000000000001500
Andersen ML, Nascimento DC, Machado RB, Roizenblatt S, Moldofsky H, Tufik S. Sleep disturbance induced by substance P in mice. Behav Brain Res 2006;167:212–218. doi: 10.1016/j.bbr.2005.09.008
doi: 10.1016/j.bbr.2005.09.008
Lieb K, Ahlvers K, Dancker K, et al. Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacology 2002;27:1041–1049. doi: 10.1016/S0893-133X(02)00369-X
doi: 10.1016/S0893-133X(02)00369-X
Schaffalitzky De Muckadell OB, Aggestrup S, Stentoft P. Flushing and plasma substance P concentration during infusion of synthetic substance P in normal man. Scand J Gastroenterol 1986;21:498–502. doi: 10.3109/00365528609015169
doi: 10.3109/00365528609015169
Wong BJ, Minson CT. Neurokinin-1 receptor desensitization attenuates cutaneous active vasodilatation in humans. J Physiol 2006;577(Pt 3):1043–1051. doi: 10.1113/jphysiol.2006.112508
doi: 10.1113/jphysiol.2006.112508
Kramer MS, Winokur A, Kelsey J, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004;29:385–392. doi: 10.1038/sj.npp.1300260
doi: 10.1038/sj.npp.1300260
Ratti E, Bellew K, Bettica P, et al. Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. J Clin Psychopharmacol 2011;31:727–733. doi: 10.1097/JCP.0b013e31823608ca
doi: 10.1097/JCP.0b013e31823608ca
Ratti E, Bettica P, Alexander R, et al. Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. J Psychopharmacol 2013;27:424–434. doi: 10.1177/0269881113480990
doi: 10.1177/0269881113480990
Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998;281:1640–1645. doi: 10.1126/science.281.5383.1640
doi: 10.1126/science.281.5383.1640
Ratti E, Carpenter DJ, Zamuner S, et al. Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia. Sleep 2013;36:1823–1830. doi: 10.5665/sleep.3208
doi: 10.5665/sleep.3208
Cytel. Compass User Manual . Cambridge, MA: Cytel Inc; 2012.
Ivanova A, Bolognese JA, Perevozskaya I. Adaptive dose finding based on t-statistic for dose-response trials. Stat Med 2008;27:1581–1592. doi: 10.1002/sim.3209
doi: 10.1002/sim.3209
US Food and Drug Administration. Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation . Washington DC: US Department of Health and Human Services; 2009.
Yang M, Morin CM, Schaefer K, Wallenstein GV. Interpreting score differences in the Insomnia Severity Index: using health-related outcomes to define the minimally important difference. Curr Med Res Opin 2009;25:2487–2494. doi: 10.1185/03007990903167415
doi: 10.1185/03007990903167415
Lewis JE, Hilditch JR, Wong CJ. Further psychometric property development of the Menopause-Specific Quality of Life questionnaire and development of a modified version, MENQOL-Intervention questionnaire. Maturitas 2005;50:209–221. doi: 10.1016/j.maturitas.2004.06.015
doi: 10.1016/j.maturitas.2004.06.015
Fraser GL, Lederman S, Waldbaum A, et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause 2020;27:382–392. doi: 10.1097/GME.0000000000001510
doi: 10.1097/GME.0000000000001510
Prague JK, Roberts RE, Comninos AN, et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2017;389:1809–1820. doi: 10.1016/s0140-6736(17)30823-1
doi: 10.1016/s0140-6736(17)30823-1
Lobo RA, Archer DF, Kagan R, et al. A 17β-estradiol-progesterone oral capsule for vasomotor symptoms in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2018;132:161–170. doi: 10.1097/AOG.0000000000002645
doi: 10.1097/AOG.0000000000002645
Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009;16:1116–1124. doi: 10.1097/gme.0b013e3181a7df0d
doi: 10.1097/gme.0b013e3181a7df0d
US Food and Drug Administration. Brisdelle Cross Discipline Team Leader Review. Silver Spring, MD: Center for Drug Evaluation and Research; 2013.
Prague JK, Roberts RE, Comninos AN, et al. Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action. Menopause 2018;25:862–869. doi: 10.1097/GME.0000000000001090
doi: 10.1097/GME.0000000000001090
US Food and Drug Administration. Clinical review of Brisdelle for the treatment of moderate to severe vasomotor symptoms associated with the menopause. Silver Spring, MD: Center for Drug Evaluation and Research; 2013.
Woods NF, Hohensee C, Carpenter JS, et al. Symptom clusters among MsFLASH clinical trial participants. Menopause 2016;23:158–165. doi: 10.1097/GME.0000000000000516
doi: 10.1097/GME.0000000000000516
Carpenter JS, Andrykowski MA. Psychometric evaluation of the Pittsburgh Sleep Quality Index. J Psychosom Res 1998;45:5–13. doi: 10.1016/s0022-3999(97)00298-5
doi: 10.1016/s0022-3999(97)00298-5
Simon JA, Portman DJ, Kaunitz AM, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause 2013;20:1027–1035. doi: 10.1097/GME.0b013e3182a66aa7
doi: 10.1097/GME.0b013e3182a66aa7